Rekover Therapeutics is looking to repair nerve damage caused by neurodegenerative diseases such as multiple sclerosis (MS). Currently, disease-modifying therapies only slow the rate of accumulating disability in patients with MS; none reverse the disability. The treatments being explored by Rekover have the potential to improve the quality of life for patients.
A spin-out of Victoria University of Wellington, Rekover and its academic collaborators have developed a compelling set of data showing the remyelination and neuro-reparative effects of a repurposed pharmaceutical product in preclinical models.